254 related articles for article (PubMed ID: 31442252)
1. High expression of the vacuole membrane protein 1 (VMP1) is a potential marker of poor prognosis in HER2 positive breast cancer.
Amirfallah A; Arason A; Einarsson H; Gudmundsdottir ET; Freysteinsdottir ES; Olafsdottir KA; Johannsson OT; Agnarsson BA; Barkardottir RB; Reynisdottir I
PLoS One; 2019; 14(8):e0221413. PubMed ID: 31442252
[TBL] [Abstract][Full Text] [Related]
2. The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.
El Ansari R; Craze ML; Miligy I; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res; 2018 Mar; 20(1):21. PubMed ID: 29566741
[TBL] [Abstract][Full Text] [Related]
3. MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
Han J; Choi YL; Kim H; Choi JY; Lee SK; Lee JE; Choi JS; Park S; Choi JS; Kim YD; Nam SJ; Nam BH; Kwon MJ; Shin YK
Breast Cancer Res Treat; 2017 Jul; 164(1):41-56. PubMed ID: 28409241
[TBL] [Abstract][Full Text] [Related]
4. The transcription factor CBFB mutations indicate an improved survival in HR+/HER2- breast cancer.
Guo L; Chen B; Zhang G; Wang Y; Cao L; Ren C; Wen L; Lin J; Wei G; Liao N
Gene; 2020 Oct; 759():144970. PubMed ID: 32711101
[TBL] [Abstract][Full Text] [Related]
5. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.
Duchnowska R; Jassem J; Goswami CP; Dundar M; Gökmen-Polar Y; Li L; Woditschka S; Biernat W; Sosińska-Mielcarek K; Czartoryska-Arłukowicz B; Radecka B; Tomasevic Z; Stępniak P; Wojdan K; Sledge GW; Steeg PS; Badve S
J Neurooncol; 2015 Mar; 122(1):205-16. PubMed ID: 25559688
[TBL] [Abstract][Full Text] [Related]
6. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
Tan RSYC; Ong WS; Lee KH; Lim AH; Park S; Park YH; Lin CH; Lu YS; Ono M; Ueno T; Naito Y; Onishi T; Lim GH; Tan SM; Lee HB; Ryu HS; Han W; Tan VKM; Wong FY; Im SA; Tan PH; Chan JY; Yap YS
BMC Med; 2022 Mar; 20(1):105. PubMed ID: 35296300
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
8. Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.
Kim JY; Lee E; Park K; Jung HH; Park WY; Lee KH; Sohn J; Lee KS; Jung KH; Kim JH; Lee KH; Im SA; Park YH
Int J Cancer; 2019 Sep; 145(6):1669-1678. PubMed ID: 30720867
[TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts.
Aleskandarany MA; Agarwal D; Negm OH; Ball G; Elmouna A; Ashankyty I; Nuglozeh E; Fazaludeen MF; Diez-Rodriguez M; Nolan CC; Tighe PJ; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Feb; 156(1):9-20. PubMed ID: 26907764
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
Joseph C; Arshad M; Kurozomi S; Althobiti M; Miligy IM; Al-Izzi S; Toss MS; Goh FQ; Johnston SJ; Martin SG; Ellis IO; Mongan NP; Green AR; Rakha EA
Breast Cancer Res Treat; 2019 Apr; 174(2):387-399. PubMed ID: 30554343
[TBL] [Abstract][Full Text] [Related]
11. miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth.
Lindholm EM; Leivonen SK; Undlien E; Nebdal D; Git A; Caldas C; Børresen-Dale AL; Kleivi K
Microrna; 2019; 8(2):155-165. PubMed ID: 30520388
[TBL] [Abstract][Full Text] [Related]
12. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
van Ramshorst MS; van der Heiden-van der Loo M; Dackus GM; Linn SC; Sonke GS
Breast Cancer Res Treat; 2016 Jul; 158(2):361-71. PubMed ID: 27357813
[TBL] [Abstract][Full Text] [Related]
13. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.
Kurozumi S; Joseph C; Sonbul S; Aleskandarany MA; Pigera M; Alsaleem M; Alsaeed S; Kariri Y; Nolan CC; Diez-Rodriguez M; Johnston S; Mongan NP; Fujii T; Shirabe K; Martin SG; Ellis IO; Green AR; Rakha EA
Breast Cancer Res Treat; 2018 Nov; 172(1):61-68. PubMed ID: 30056565
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
16. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
[TBL] [Abstract][Full Text] [Related]
17. MiR-4728-3p could act as a marker of HER2 status.
Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
[TBL] [Abstract][Full Text] [Related]
18. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
